Literature DB >> 3403324

Elective lower neck irradiation: 5000 cGy/25 fractions versus 4050 cGy/15 fractions.

W M Mendenhall1, J T Parsons, R R Million.   

Abstract

This is an analysis of 171 patients treated with irradiation alone for squamous cell carcinoma of the head and neck who received elective radiation therapy to the clinically negative low neck. All patients have a minimum follow-up of 2 years and 63% have had at least 5 years of follow-up. Patients were excluded from this analysis if they developed recurrent disease at the primary site or in the upper neck. The majority of patients, 162/171, were treated with one of 2 dose-fractionation protocols: 5000 cGy/25 fractions (5 fractions per week for 5 weeks) and 4050 cGy/15 fractions (5 fractions per week for 3 weeks). Patients were subdivided into four risk groups based on the estimated likelihood of subclinical disease in the neck. There was no difference in the rate of the neck disease control between these 2 dose-fractionation protocols. We conclude that 5000 cGy/25 fractions and 4050 cGy/15 fractions are equally effective in sterilizing occult neck disease.

Entities:  

Mesh:

Year:  1988        PMID: 3403324     DOI: 10.1016/s0360-3016(98)90027-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Principles and techniques of irradiation for the N0 neck.

Authors:  F Eschwege; A Bridier; B Luboinski
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

2.  Regional recurrence of oropharyngeal cancer after definitive radiotherapy: a case control study.

Authors:  Karin Söderström; Per Nilsson; Tina Dalianis; Elisabeth Kjellén; Björn Zackrisson
Journal:  Radiat Oncol       Date:  2015-05-27       Impact factor: 3.481

3.  Expression of E-cadherin, alpha-catenin, and beta-catenin in the process of lymph node metastasis in oral squamous cell carcinoma.

Authors:  N Tanaka; T Odajima; K Ogi; T Ikeda; M Satoh
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.